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In multiple sclerosis (MS), a chronic inflammatory relapsing demyelinating disease, failure to control or repair 
damage leads to progressive neurological dysfunction and neurodegeneration. Implantation of neural stem 
cells (NSCs) has been shown to promote repair and functional recovery in the acute experimental autoimmune 
encephalomyelitis (EAE) animal model for MS; the major therapeutic mechanism of these NSCs appeared to 
be immune regulation. In the present study, we examined the efficacy of intraventricularly injected NSCs in 
chronic relapsing experimental autoimmune encephalomyelitis (CREAE), the animal disease model that is 
widely accepted to mimic most closely recurrent inflammatory demyelination lesions as observed in relapsing–
remitting MS. In addition, we assessed whether priming these NSCs to become oligodendrocyte precursor cells 
(OPCs) by transient overexpression of Olig2 would further promote functional recovery, for example, by con-
tributing to actual remyelination. Upon injection at the onset of the acute phase or the relapse phase of CREAE, 
NSCs as well as Olig2-NSCs directly migrated toward active lesions in the spinal cord as visualized by in 
vivo bioluminescence and biofluorescence imaging, and once in the spinal cord, the majority of  Olig2-NSCs, 
in contrast to NSCs, differentiated into OPCs. The survival of Olig2-NSCs was significantly higher than that 
of injected control NSCs, which remained undifferentiated. Nevertheless, both Olig2-NSCs and NSC signifi-
cantly reduced the clinical signs of acute and relapsing disease and, in case of Olig2-NSCs, even completely 
abrogated relapsing disease when administered early after onset of acute disease. We provide the first evidence 
that NSCs and in particular NSC-derived OPCs (Olig2-NSCs) ameliorate established chronic relapsing EAE 
in mice. Our experimental data in established neurological disease in mice indicate that such therapy may be 
effective in relapsing–remitting MS preventing chronic progressive disease.
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for inducing remyelination and, with that, the slowing 
or preventing of axonal degeneration. Unprecedently, 
a potentially clinicaly relevant source for transplantable 
remyelinating cells has become within reach.
Indeed, endogenous NSCs residing in specific germi-
nal niches in the CNS are thought to produce new oligo-
dendrocyte precursor cells (OPCs) and so to contribute 
to myelin repair after a demyelinating assault. However, 
the efficacy of these endogenous NSCs in contribut-
ing to myelin repair is limited (for a review, see 24). 
Transplantation of exogenous NSCs signifies an alterna-
tive and potentially more efficient therapeutic approach 
to accomplish remyelination in MS. A number of stud-
ies in the acute experimental autoimmune encephalomy-
elitis (EAE) mouse model for MS (for a review, see 7) 
INTRODUCTION
Multiple sclerosis (MS) is one of the most common 
neuroimmunological disorders of the central nervous sys-
tem (CNS). It is distinguished by multiple autoimmune 
inflammatory assaults in the CNS, resulting in oligoden-
drocyte impairment and/or degeneration, which lead to 
axonal demyelination, injury, and dysfunction. Whereas 
the development of anti-inflammatory drugs for MS has 
made significant progress in the last decades, strategies 
for remyelination and axonal restoration require further 
development and refinement. Importantly, developments 
in stem cell research, in particular the discovery of induced 
pluripotent stem (iPS) cells enabling the generation of infi-
nite numbers of autologous neural stem cells (NSCs) (29), 
have revived the idea of cell-based therapy as an approach 
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have shown that NSCs indeed have a beneficial effect 
after grafting and significantly reduced clinical scores. 
Recently, human neural stem cells were administered to 
nonhuman primates in which EAE was induced and simi-
lar observations were made (23). However, the beneficial 
effect on acute EAE symptoms appeared not (or at least 
not directly) to be achieved by promotion of remyelina-
tion but by the reduction of inflammation via various 
trophic, immunomodulatory, and even T-cell apoptosis-
inducing factors produced by the undifferentiated NSCs 
(11–13,24–27). These studies reveal that grafted undif-
ferentiated NSCs, although optimally equipped for hom-
ing to the lesions, show only marginal differentiation into 
remyelinating oligodendrocytes at the site of the lesion. 
In a previous study, we have primed NSCs toward an oli-
godendrocyte cell lineage by the induced overexpression 
of Olig2 (9) before transplanting them into the demyeli-
nated corpus callosum of cuprizone-fed mice to induce 
chronic demyelination (31). We compared the long-term 
survival and functional behavior of these Olig2-NSCs 
with implanted undifferentiated NSCs and found that, 
in contrast to undifferentiated NSCs, Olig2-NSCs sur-
vived and developed into myelinating oligodendrocytes 
contributing to the remyelination of the corpus callosum 
(31). Recently, a similar approach with human NSCs was 
successful in transplantation experiments in the lesioned 
white matter of rat spinal cord, namely, that grafted 
human Olig2-NSCs, in contrast to undifferentiated NSCs, 
significantly aided remyelination and promoted locomo-
tor recovery (17).
Obviously, the conditions in the demyelination 
lesions in the animal models mentioned above are not 
comparable to the inflammatory conditions in demyeli-
nation lesions in relapsing–remitting MS; the presence 
of reactive T cells, monocytes, macrophages, activated 
microglia, and astrocytes as well as the proinflamma-
tory milieu of, for example, cytokines and chemokines 
produced by these cells, may affect the migration, sur-
vival, and remyelination activity of implanted NSCs and 
Olig2-NSCs.
Therefore, in the present study, we have investigated 
the survival, migration, and functional behavior of NSCs 
as well as Olig2-NSCs after intraventricular injection in a 
chronic inflammatory model of MS, the chronic relapsing 
EAE mouse, the animal disease model, which is widely 
accepted to sufficiently mimic inflammatory demyelina-
tion lesions as observed in MS.
MATERIALS AND METHODS
Animals
The EAE implantation experiments were performed 
in 8- to 10-week-old female FVB (n = 32) and Biozzi 
ABH (n = 24) mice supplied by Harlan (Harlan, Horst, 
The Netherlands; http://www.harlan.com/about_harlan_ 
laboratories). In addition, we have used FVB luciferase-
green fluorescent protein (GFP)-actin transgenic mice 
(kindly donated by Christopher Contag, Stanford Uni-
versity, San Francisco, CA, USA) for the isolation of 
luciferase-GFP-positive NSCs. All mice were housed 
under standard conditions with free access to food and 
water. All animal experiments were designed and carried 
out in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and 
Regulations of the Local Experimental Animal Committee.
Experimental Autoimmune Encephalomyelitis (EAE)
FVB Mice. Female FVB mice were injected subcuta-
neously with a sonicated emulsion consisting of 200 μg 
human recombinant myelin-oligodendrocyte glycoprotein 
(MOG) 35–55 emulsified in incomplete Freund’s adju-
vant (IFA) supplemented with 60 μg killed Mycobacteria 
tuberculosis on days 0 and 7 as described previously 
(1–4). Immediately and 24 h after immunization, the FVB 
mice were also injected IP with 200 ng of pertussis toxin, 
derived from Bordetella pertussis (Speywood, Porton 
Down, UK) dissolved in sterile water. In FVB mice, this 
induction protocol induces a monophasic acute form of 
EAE. EAE FVB mice were included in the experimen-
tal studies that started EAE symptoms within days 10–12 
after immunization.
Biozzi ABH Mice. To examine the effects of NSC 
implantation in chronic relapsing–remitting EAE in 
which myelin damage is more prominent in the relapse 
phases (4), Biozzi ABH mice were used. The same 
immunization protocol was used as described above, in 
which lyoph ilized homologous spinal cord in phosphate-
buffered saline (PBS, 0.1 M) replaced the MOG peptide. 
Animals were weighed daily and assessed for neurological 
signs from day 7 postinoculation. EAE Biozzi mice were 
included in the experimental studies with EAE symptoms 
starting within days 10–12 after immunization.
Signs of EAE were scored as follows: 0 = normal, 
1 = limp tail, 2 = impaired righting reflex, 3 = partial hind-
limb paralysis, 4 = total hind-limb paralysis, 5 = oribund 
(euthanized).
Neural Stem Cells (NSCs)
For potential future clinical application of NSCs, 
pluripotent sources like embryonic stem cells, in par-
ticular, induced pluripotent stem (IPS) cells, may be 
the source of choice for NSCs; such NSCs are not spe-
cifically proned for oligodendrocyte differentiation. 
Therefore, also in the present study, we have chosen 
to use E14 telencephalic NSCs, that is, NSCs that are 
not (yet) involved in oligodendrocyte formation. The 
NSCs were isolated from the brain of either luciferase-
GFP-actin transgenic mouse embryos or Biozzi ABH 
embryos at embryonic day E14. Briefly, the brain was 
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cut into small pieces at room temperature, and follow-
ing mechanical trituration in ice-cold phosphate-buff-
ered saline (PBS, 0.1 M), small pieces of tissue were 
incubated with accutase (Sigma-Aldrich, St. Louis, 
MO, USA; http://www.sigmaaldrich.com) for 10 min at 
37°C. After repeated trituration, the cell suspension was 
passed through a cell strainer (70 μm pore size; Falcon, 
Franklin Lakes, NJ, USA; http://www.bdbiosciences.
com) and seeded (1–1.5 million cells) in T25 cm2 tissue 
culture flasks (Nunc, Roskilde, Denmark; http://www.
nuncbrand.com) containing proliferation medium, which 
consisted of neurobasal medium (Invitrogen, Breda, The 
Netherlands; http://www.invitrogen.com) supplemented 
with B27 (2%; Invitrogen), human recombinant epider-
mal growth factor (20 ng/ml; Invitrogen), basic fibro-
blast growth factor (20 ng/ml; Invitrogen), glutamax 
(1%; Invitrogen), primocin (100 μg/ml), and heparin 
(5 μg/ml; Sigma-Aldrich) in a humidified 5% CO2/95% 
air incubator at 37°C. Luciferase expression in isolated 
and cultured NSCs isolated from luciferase-GFP- actin 
transgenic FVB mice was verified with a standard 
luciferase assay in a bioluminometer. The NSCs iso-
lated from the ABH mice were labeled before implanta-
tion either by transfection of the firefly luciferase gene 
(see below) or by uptake of dragon green fluorophores 
(Bangs Laboratories, Inc., Fishers, IN, USA): 1.7 μl 
(approximately 5 × 106 particles) of fluorophores were 
added per milliliter of medium 24 h before the implan-
tation of the cells. Labeling efficiency was approxi-
mately 90%.
Gene Transfection
Overexpression of Olig2 was induced in NSCs iso-
lated from the luciferase-GFP transgenic FVB mice by 
transfection of an internal ribosome entry site plasmid 
(pIRES) expression vector containing the Olig2 gene; 
the parallel undifferentiated NSC group of FVB mice 
received a similar control transfection with GFP. NSCs 
isolated from Biozzi ABH mice were transfected with the 
same pIRES vector containing the firefly luciferase gene 
or the Olig2 gene. In both cases, transfection was per-
formed using an Amaxa electroporation protocol (Amaxa 
GmbH, Cologne, Germany; http://www.amaxa.com) spe -
cifically designed for the transfection of embryonic 
mouse NSCs. The transfection efficiency of this proce-
dure for mouse NSCs is approximately 85% and results 
in the transient expression of the transfected gene lasting 
up to 10–12 days.
Implantation of NSCs
FVB Mice. To examine the effect of NSC implanta-
tion in the acute phase of EAE, FVB mice were divided 
into three groups: group 1, received an injection at the 
first signs of acute EAE (n = 10); group 2, received an 
injection after recovering from the first episode of dis-
ease (n = 8); and group 3, the control group that was 
not EAE immunized (n = 4). Using a standard stereo-
tactic procedure, half of the mice in groups 1 and 2 
received an intraventricular injection of 1.5 × 105 NSCs 
while the other half received 1.5 × 105 Olig2-NSCs; 
stereotactic coordinates used (in relation to Bregma) 
anterior–posterior (−0.5), lateral (−1.0), and vertical 
(−2.6) according to the stereotaxic mouse brain atlas 
of Paxinos and Franklin (22). The mice in group 3 only 
received Olig2-NSCs. Sham mice (n = 2) were injected 
with only PBS. 
Biozzi Mice. To examine the effects of NSC implants 
in the demyelinating relapsing–remitting form of EAE, 
EAE was induced in Biozzi ABH mice. Once clinical 
EAE was observed, the mice were randomly allocated 
into two groups: one group (n = 8) received an intraven-
tricular implantation (same protocol as described above) 
at first signs of the primary acute attack, and the second 
group (n = 6) was injected intraventricularly at the onset 
of the first relapse. Similar to the EAE FVB mice, half of 
each group received 1.5 × 105 NSCs, while the other half 
received 1.5 × 105 Olig2-NSCs.
In Vivo Bioluminescence and Fluorescence Tracing  
of Implants
For the in vivo tracking of the luciferase-positive 
cell grafts, each animal was imaged three to four times 
per week with the use of the IVIS Imaging System 200 
Series of Xenogen Corporation (Caliper Life Sciences, 
Alameda, CA, USA; http://www.caliperls.com). At each 
imaging session, each mouse received an IP injection 
of d-luciferin (300 mg/kg) in normal physiological salt 
solution. Ten minutes after the d-luciferin injection, 
animals were anesthetized with isoflurane (2.5% iso-
flurane in oxygen, 1.5 L/min) and placed in a standard-
ized position in the chamber of a charge-coupled device 
camera system. The Dragon green-labeled cells were 
traced by using the fluorescein filter sets of the IVIS. 
The Living Image 2.5 software program (Xenogen 
Corporation, Caliper Life Sciences) was used for data 
analysis. Images representing luciferin and fluorescein 
light intensity, ranging from blue to red (for luciferase) 
and from black to yellow (fluorescein), were merged 
with the reference image to enable anatomical local-
ization. Images were displayed, and regions of interest 
were quantified in terms of radiance [photons/s/cm2/
steradian (sr)].
Immunohistochemistry
At 8–10 days after implantation, that is, day 12 in the 
FVB and day 50 in the Biozzi mice, animals were per-
fused transcardially with 4% paraformaldehyde (PFA) 
under isoflurane anesthesia. In addition, as controls, EAE 
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mice that did not receive an implant were perfusion-
fixed at various time points. Spinal cords were excised 
and sectioned on a cryostat. Sections were stained with 
cresyl violet for an overview of the pathology or stained 
with Luxol Fast Blue to examine myelin damage. Most 
of the tissues were used for immunohistochemistry. To 
identify luciferase-GFP or luciferase-labeled implanted 
cells, immunostaining was performed after heat-induced 
antigen/epitope retrieval (HIER) (10 mM sodium cit-
rate, 0.05% Tween 20, pH 6.0) (required for luciferase 
immunostaining) using goat anti-luciferase (ab3256; 
Chemicon, Millipore, Amsterdam, The Netherlands; 
http://www.millipore.com) or rabbit anti-GFP (ab290; 
Abcam, Cambridge, MA, USA; http://www.abcam.com). 
To evaluate the survival and differentiation of the cell 
implants, the following primary antibodies directed against 
marker proteins specifically expressed by freshly differ-
entiated oligodendrocytes, neurons, or astrocytes were 
used for astroblasts, anti-S100β (11420, 1:400; ICN 
Biomedicals, Inc., Irvine, CA, USA; http://www.mpbio.
com) and anti-glial fibrillary acidic protein (GFAP) 
(mab3402; Millipore-Chemicon); for neuro blasts, 
anti-doublecortin (DCX) (AB5910, 1:500; Millipore-
Chemicon); and for oligodendrocyte precursor cells, anti- 
RIP (mab1580; Millipore-Chemicon) or anti-NG2 (ab5320; 
Millipore-Chemicon). Subsequently, various fluorescent 
secondary antibodies were used to visualize the specific 
primary immunoreaction product in single and double 
immunohistochemical staining.
Chemotaxis Assay
NSCs and Olig2-NSCs migration in response to the 
chemokines CXCL12 [chemokine (C-X-C motif) ligand 
12] and CXCL9 was assessed using a 48-well chemo-
taxis microchamber (Neuroprobe, AP48, Gaithersburg, 
MD, USA). A volume of 28 μl of chemokine solution 
(in neurobasal medium at concentrations of 10 nM) or 
control medium (neurobasal medium) was added to the 
lower wells. A total of 5 × 104 cells per 50 μl were used in 
the assay. The chamber was incubated at 37°C, 5% CO2, 
in a humidified atmosphere for 4–5 h. After the incuba-
tion, the filter was fixed in Fast Green in 100% methanol 
with the concentration of 0.002 g/L (Diff-Quik Fix, Dade 
Behring, Düdingen, Fribourg, Switzerland) and stained 
twice, first in stain solution 1, containing 1.22 g/L eosin 
G in phosphatase buffer with the pH value of 6.6 (Diff-
Quik), and then in stain solution 2, containing 1.1 g/L 
thiazine dye in phosphate buffer with pH 6.6. After stain-
ing, the filter membrane was cleaned on the upper side 
and dried. Migrated cells were counted with a scored 
eyepiece [3 fields (1 mm2) per well], and migrated cells 
per chamber were calculated. The data are presented as 
percentages of control migration ± SEM and were ana-
lyzed by Student’s t test. Control migration in response 
to neurobasal media is set to 100%. Values of p < 0.05 
were considered significant.
RT-PCR
Total RNA was isolated from NSCs and Olig2-NSCs. 
Cells were lysed in guanidinium isothiocyanate/mercap-
toethanol buffer, and RNA was extracted with phenol- 
chloroform and precipitated by using isopropanol. To 
degrade possible genomic DNA traces, DNase (Fermentis) 
was used. One microgram of total RNA was used for 
reverse transcriptase (RT) reaction and 2 μl of the RT reac-
tion were used in subsequent PCR amplification using fol-
lowing primer pairs: chemokine (C-X-C motif) receptor 4 
(CXCR4), sense 5′-TCCAAGGGCCACCAGAAGCG-3′, 
antisense 5 ′-AACTTGGCCCCGAGGAAGGC-3 ′; 
CXCR3, sense 5′-GCCAAGCCATGTACCTTGAGGTTA
GT-3′, antisense 5′-AGGTGTCCGTGCTGCTCAGG-3′. 
Cell Counting
Quantitative analysis of implanted cells was carried 
out by counting GFP+ or dragon green fluorophores+ 
cells in coronal cryostat sections of the spinal cord 
using a fluorescent microscope equipped with a Leica 
DFC300FX camera and the Leica microsystem LAS 
program (Leica, Heerbrugg, Switzerland; http://www.
leica.com). The spinal cord was cut in three equal seg-
ments containing, respectively, the cervical, thoracic, 
and lumbar spinal cord. Every 10th section (14 µm) 
of this segment was collected and put on glass slides 
for immunofluorescent staining procedures. For each 
spinal segment, 10 subsequent sections were analyzed 
and used for cell counting. The number of cells in 
the spinal cord was calculated by the summation of 
the number of cells in each of the three spinal cord 
segments multiplied by a factor 10. Quantification of 
different cell types was performed based on cell type-
specific double immunostaining (GFP or dragon green 
fluorophores/cell-specific marker). Statistical analysis 
of the results of all animals in each group was per-
formed using Student’s t test; values of p < 0.05 were 
considered significant.
RESULTS
EAE in FVB Mice Strain
Induction of EAE in the FVB mice results in an 
acute monophasic clinical course (Fig. 1A). The typi-
cal pattern of disease progress started at days 10–12 
after immunization, with a peak at days 17–18 and 
a recovery that was almost complete by days 27–28. 
The arrows in Figure 1A indicate the time points of 
injection of the NSCs. The clinical signs in this mono-
phasic acute form of EAE are the result of exten-
sive inflammation with substantial cell infiltration 
(Fig. 1B) and edema formation in the spinal cord with 
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only minor contribution of demyelination and sub-
sequent axonal injury.
Intraventricularly Injected Neural Stem Cells Migrate 
Only to Active EAE Lesions
Luciferase-labeled NSCs and luciferase-labeled 
 Olig2-NSCs were implanted in the FVB mice intra-
ventricularly, and their distribution and migration were 
monitored using the IVIS 200 bioluminescence imaging 
system. In the first week after implantation, the migra-
tion of the implanted cells from the site of intraventricular 
injection toward the spinal cord depended on the pres-
ence of active EAE lesions (Fig. 2). Quantification of the 
bioluminescence in the EAE mice demonstrated that the 
initial signal at the site of deposition in the brain ventricle 
decreased whereas the signal in the spinal cord increased 
(Fig. 2A–D, G). No differences were observed between 
the migration of NSCs or Olig2-NSCs in the EAE mice, 
indicating a similar responsiveness to the signals from the 
spinal cord lesions. In control mice and in mice that had 
been implanted intraventricularly after recovery from the 
clinical attack of EAE relapse (late EAE, day 30, Fig. 1), 
no migration of implanted cells toward the spinal cord 
was detected (Fig. 2C, F, G). This illustrated that only 
active lesions produce attractants for the implanted cells. 
After a week, the level of bioluminescence activity in the 
spinal cord and the brain stabilized.
We analyzed the expression of the major chemokine 
receptors of NSCs, CXCR3 and CXCR4, both in undiffer-
entiated NSCs and Olig2-NSCs and performed a chemo-
taxis assay for the chemokines CXCL9 and CXCL12. The 
results, depicted in Figure 3, did not reveal a significant 
difference between NSCs and Olig2-NSCs, confirming 
the similar migratory capacities of NSCs and Olig2-NSCs 
as observed in the implantation experiments.
NSCs and Olig2-NSCs Inhibit the Development  
of Acute EAE
Intraventricular injection of both NSCs and 
 Olig2-NSCs induced a significant inhibition in the devel-
opment of clinical EAE in FVB mice (Fig. 4) following 
the injection of NSCs and Olig2-NSCs on day 12, when 
mice exhibited a limp tail (clinical score of 1). 
Immunohistochemical analysis of the spinal cord of 
FVB-EAE mice following intraventricular injections with 
labeled NSCs or Olig2-NSCs at days 20–23 revealed the 
presence of intraventricularly injected cells in the spinal 
cord (Fig. 5A–F). The posterior, lateral, and anterior funiculi 
of the EAE-spinal cord were highly cellular and contained 
numerous infiltrating cells (Fig. 5A). The luciferase-GFP-
positive injected cells were detected among these cell infil-
trations in the funiculus areas. Quantification of the number 
of implanted cells in these sections of spinal cord that were 
still present 10 days after injection revealed a slightly, but 
not significantly, higher survival rate for the Olig2-NSC in 
comparison to the NSCs. With double immunostaining, the 
identity of the differentiation direction of the injected cells 
was determined (Fig. 5G–H). The majority of the injected 
NSCs were still undifferentiated as revealed by their stain-
ing with anti-nestin antibodies, with only a small percent-
age of cells differentiating toward an OPC type (NG2 or 
RIP positive) and relatively few toward neurons (double-
cortin staining) or astrocytes (S100 or GFAP staining). The 
majority of the injected Olig2-NSCs in the EAE spinal 
Figure 1. Experimental autoimmune encephalomyelitis (EAE) disease course in FVB mice. (A) The clinical scores of EAE in FVB mice 
(n = 10; ±SEMs) reveal a clear monophasic pattern. The arrows indicate the time points of intraventricular injection of neural stem cells 
(NSCs) and Olig2-NSCs. (B) Sections of spinal cord stained for cresyl violet (CV) taken at peak of clinical score show extensive cellular 
infiltration in the funiculus white matter; compared with healthy control mice. Scale bar: 100 μm.
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cord, however, developed into OPCs (NG2 positive) as 
was expected because of their OPC-primed state. However, 
none of these cells expressed MBP, indicating that none of 
them actually reached a mature myelinating stage. This is 
in line with the fact that demyelination rarely occurs in the 
primary acute disease episodes in this monophasic EAE 
model and so no new remyelinating cells are required. 
EAE in Biozzi ABH Mice
Induction of EAE in the Biozzi ABH mice resulted in a 
chronic relapsing–remitting pattern of disease (Fig. 6A) in 
which the first attack (the acute phase) started between days 
10 and 12, with a peak at day 22 and a return to normal scores 
around day 30. As in the monophasic course of FVB mice, 
the clinical signs in this acute form of EAE are the result of 
extensive cell infiltration and edema in the spinal cord. A 
second neurological attack (relapse) was observed 15 days 
later, reaching a plateau at score 3 from days 55 to 65, until 
the clinical score remitted to almost baseline scores around 
day 70 (Fig. 6B); the clinical signs in the relapsing disease 
in the Biozzi mice are initiated by cell infiltration, but they 
are particularly associated with subsequent demyelination, 
as has been extensively described before for this model (4).
NSCs and Olig2-NSCs Delay or Prevent the Onset of 
Relapses in Biozzi EAE Mice
To investigate the effect of intraventricular injections 
of NSCs and the OPC-primed Olig2-NSCs on the clini-
cal course of EAE in the Biozzi mice, we injected both 
cell suspensions at day 12 at the first signs of clinical 
Figure 2. Distribution pattern of luciferase-labeled NSCs and Olig-NSCs in brain and spinal cord, as measured by bioluminescent 
intensity (total flux of photons), in the first week after their intraventricular implantation in EAE FVB mice. (A, B) A gradual decrease 
in bioluminescent activity in the brain and a concomitant increase in the spinal cord point to the migration of NSCs and Olig2-NSCs 
toward the spinal cord containing active EAE lesions. (C) Depicts in more detail the increase in bioluminescence activity in the spinal 
cord of EAE mice after intraventricular injections. (D, E) Intraventricular injection of luciferase-labeled NSCs and Olig-NSCs in con-
trol mice (no EAE) or at a late stage of EAE do not lead to an increase in bioluminescent intensity in the spinal cord. (F) Summarizing 
graph showing the distribution pattern in the spinal cord at the indicated conditions. (G) Examples of IVIS scans in control and 
implanted mice at 3 days after intraventricular injection. For each group: n = 5 (±SEMs).
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Figure 3. Chemokine signaling in NSCs and Olig2-NSCs. (A) RT-PCR analysis shows that NSCs 
as well as Olig2-NSCs express the major chemokine receptors CXCR3 and CXCR4. (B) Moreover, 
NSCs and Olig2-NSCs have an equal migratory response to the chemokines CXCL12 and CXCL9 in 
a chemotaxis assay. The data of the chemotaxis assay in (B) are presented as percentages of control 
migration (n = 3, ±SEM); control migration in response to neurobasal media is set to 100%.
Figure 4. EAE disease course in FVB mice following stem cell transplantation. The intraventricular injec-
tion of NSCs (n = 5, ±SEM) or Olig2-NSCs (n = 5, ±SEM) at the beginning of EAE (arrow) blocks the 
development of clinical EAE; untreated disease course taken from Figure 1A (data generated for Figs. 1 
and 4 were collected in one and the same experiment, at the same time). 
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Figure 5. Immunohistochemical analysis of spinal cord of FVB-EAE mice after intraventricular injections with labeled NSCs 
or Olig2-NSCs. (A, B) Green fluorescent protein (GFP)-labeled cells have migrated from the intraventricular injection site in 
the brain to the spinal cord and are located in the lesions (GFP/Hoechst nuclear staining). (C–F). Double immunostaining for 
GFP and RIP shows examples of injected Olig2-NSCs that differentiated into oligodendrocyte precursor cells (OPCs). (G) The 
bar graph shows the number of intraventricularly injected Olig2-NSCs and NSCs that were found in the spinal cord of EAE FVB 
mice (n = 5, mean ± SD) (H) Quantification of the differentiation pattern of the injected NSCs and Olig2-NSCs found back in the 
spinal cord shows that a majority of the Olig2-NSCs differentiated into OPCs, whereas most of the NSCs stayed undifferentiated 
(nestin-positive) (n = 5, mean ± SD; *p ≤ 0.05, Student’s t test). Scale bars: 100 μm (for A, B) and 50 μm (for C–F).
Figure 6. EAE disease course in Biozzi ABH mice. (A) The clinical scores of EAE in these mice (n = 10; ±SEMs) reveal a more 
chronic pattern with a primary response and remittance phase followed by a relapse approximately 50 days after immunization; the 
relapse pattern shows a typical extended flattened peak of clinical score. Arrows indicate the time points of intraventricular injections 
of NSCs and Olig2-NSCs. (B) Sections of spinal cord stained for Luxol Fast Blue (LFB) taken from control mice and EAE Biozzi mice 
at the peak of the relapse show demyelination in the funiculus white matter. Scale bar: 100 μm.
INTRAVENTRICULAR INJECTION OF OLIg2-NSCs IN EAE MICE 1891
Figure 7. EAE disease course in Biozzi ABH mice after intraventricular NSCs and Olig2-NSCs injections. NSCs and Olig2-NSCs 
(both groups n =  4) injected intraventricularly at the onset of acute EAE (arrow) directly prevent the further development of clinical 
signs of EAE. Moreover, the injection of NSCs (squares) significantly delays the development of subsequent relapse and abolishes the 
occurrence of a typical extended score peak; the Olig2-NSCs injections (triangles) appear to completely prevent the occurrence of a 
relapse in Biozzi EAE mice (untreated disease course taken from Fig. 6A).
disease (Fig. 7). Like in FVB mice, both intraventricu-
larly injected cell suspensions affected the clinical score 
in Biozzi mice with an even more dramatic inhibition 
of disease development, which resulted in the lack of 
neurological signs of EAE by day 20. We continued 
to monitor these Biozzi mice for the appearance of a 
relapse and surprisingly noted that this relapse was sig-
nificantly delayed by approximately 10 days with the 
typical extended peak of paresis significantly shortened 
in case of NSCs injections; remarkably, in the case of 
Olig2-NSCs injections, relapsing disease was com-
pletely inhibited (Fig. 7).
Intraventricularly Injected NSCs Migrate Also to Active 
Relapse EAE Lesions
In order to investigate the migratory response of 
intraventricularly injected NSCs to the lesioned spinal 
cord in the relapse phase, luciferase or dragon green 
fluorophore-labeled NSCs and Olig2-NSCs were intra-
ventricularly injected in Biozzi mice at the onset of the 
relapse, when mice exhibited a score of 1, about 50 days 
after immunization. Bioluminescence and fluorescence 
in vivo monitoring revealed that NSCs and Olig2-NSCs 
migrated from the site of injection toward the spinal 
cord lesions (Fig. 8). This indicated that these lesions 
in relapse produced sufficient chemotactic signals to 
attract the implanted cells.
NSCs and Olig2-NSCs Implanted at the Onset  
of Relapsing Disease Inhibit the Development of 
Clinical EAE
Next, we examined the impact of injecting NSCs 
and Olig2-NSCs during established EAE at the onset 
of the clinical relapse in Biozzi mice (Fig. 9). Like in 
the primary acute stage, both NSCs and Olig2-NSCs 
inhibited the development of clinical paresis to severe 
disability as observed in the untreated control EAE 
mice. When the clinical scores remitted and returned to 
0.5 approximately 10 days after injection, the mice were 
perfused for immunohistochemical analysis (Fig. 10). 
Immunohistochemical analysis of the spinal cord of these 
mice revealed the presence of intraventricularly injected 
dragon green fluorophore-labeled cells in the more super-
ficial regions of the posterior, lateral, and anterior funicu-
lus of the spinal cord (Fig. 10A–F). Quantitative analysis 
of the presence, distribution, and differentiation pattern 
of the NSCs and Olig2-NSCs revealed similar patterns as 
described for NSCs and Olig2-NSCs injected at the onset 
of the acute EAE in the FVB mice (Fig. 10G, H); how-
ever, the total number of cells found in the spinal cord 
of Biozzi mice after injection at the onset of the relapse 
was almost double in comparison to the studies in FVB 
mice (Fig. 5G, H). Similar to the FVB mice, a majority 
of the injected Olig2-NSCs, in contrast to the undiffer-
entiated injected NSCs, started to differentiate into early 
OPCs in the spinal cord at the relapse phase in Biozzi 
ABH mice. The rapid inhibitory effect on cell infiltration 
by the intraventricularly injected NSCs and Olig2-NSCs 
at the start of the relapse in the Biozzi mice prevented 
the occurrence of wide-scale demyelination responsible 
for the otherwise chronic clinical episode. However, in 
contrast to the NSCs, the Olig2-NSC-derived OPCs 
contributed to an indeed only limitedly required remye-
lination and maturated into oligodendrocytes. Electron 
microscopy revealed the presence of these injected 
Olig2-NSC-derived oligodendrocytes that contributed to 
myelin sheath formation (Fig. 11); these injected cells 
could be identified in electron microscopy sections by 
the large electron-dense particles of the dragon green 
fluorophores (Fig. 11A–E).
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Figure 9. EAE progression and clinical scoring in Biozzi mice after the injection of NSCs and Olig2-NSCs at the onset of a relapse 
(arrow). Both types of cell injections (squares and triangles, n = 4 ± SEM for both groups) directly prevent the progression of a relapse 
and reduce the clinical score (untreated disease course taken from Fig. 6A). 
Figure 8. Distribution pattern of luciferase-labeled NSCs (A) and dragongreen fluorophore labeled Olig2-NSCs (B) in brain and spi-
nal cord, as measured by bioluminescent or biofluorescent intensity (total flux of photons), in the first week after their intraventricular 
implantation in EAE Biozzi mice. (A) A gradual decrease in bioluminescent activity in the brain and a concomitant increase in the spi-
nal cord point to the migration of NSCs toward the spinal cord containing active EAE lesions; (A’’) example of IVIS-bioluminescence 
scans taken from a Biozzi EAE mouse at days 1, 2, 4, and 7 after intraventricular injection. (B) A similar gradual decrease as in 
bioluminescence was seen in biofluorescent activity in the brain and a concomitant increase in the spinal cord reflecting the migration 
of Olig2-NSCs toward the spinal cord containing active EAE. For each group: n = 5 (±SEMs).
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DISCUSSION
Neural stem cells (NSCs) have been reported to be 
effective as a therapeutic strategy for neurodegenerative 
disorders such as the inflammatory demyelinating and 
neurodegenerative disease multiple sclerosis (MS). In 
acute EAE, implanted undifferentiated NSCs have been 
shown to promote repair and functional recovery pre-
dominantly by releasing a milieu of both neuroprotective 
factors and anti-inflammatory molecules (11–13,24–27). 
In the present study, we investigated whether NSCs also 
exert this effect in chronic relapsing EAE, the animal 
model that mimics the relapsing–remitting form of MS 
more closely. In addition, we wanted to test whether 
priming these NSCs to become OPCs by transient overex-
pression of Olig2 (9,31) could further promote the repair 
process by contributing in remyelination activity.
Our results of intraventricular implantation of NSCs at 
the onset of acute EAE disease confirm previous obser-
vations that undifferentiated NSCs are able to reduce the 
clinical signs of EAE associated with the primary acute 
or chronic response to EAE. No obvious differences 
were observed between NSCs and OPC-primed NSCs 
 (Olig2-NSCs), suggesting that remyelination activity was 
not significantly contributing to these effects during this 
acute phase. Similar effects were observed when NSCs 
or Olig2-NSCs were injected at the onset of a relapse 
in Biozzi EAE mice, which are generally considered to 
mimic established (chronic) neurological disease in MS 
patients the most closely. In addition, we found that NSCs 
or Olig2-NSCs injected intraventricularly at the onset of 
the very first signs of disease induced a delay or a com-
plete inhibition, respectively, of the occurrence of a later 
relapse. These data suggest that transplanted NSCs may 
interfere with T-cell activity, B cell responses, or indeed 
microglia/macrophage activation at the onset of the 
relapse either at the local level in the spinal cord or at a 
more peripheral level, for instance, in the lymph nodes; 
extensive research is needed to elucidate the underlying 
cellular and molecular mechanisms.
Various studies have shown that forced expression 
of the transcription factor Olig2 in NSCs promote their 
differentiation into OPCs (9,21). Transient overexpres-
sion of Olig2 in NSCs primed these cells to become 
OPCs after stereotactic injection in the corpus callosum 
of cuprizone-fed mice, an animal model for demyelina-
tion. In contrast to control NSCs, Olig2-NSCs were able 
Figure 10. Immunohistochemical analysis of the spinal cord of Biozzi EAE mice that received intraventricular injections with labeled 
NSCs or Olig2-NSCs at the onset of the relapse. Spinal cord was collected at day 10 after injection (see Fig. 9). (A) Cresyl violet-stained 
section of Biozzi EAE spinal cord. (B) GFP-labeled cells have migrated from the intraventricular injection site in the brain to the spinal 
cord and are located in the lesions (GFP/Hoechst nuclear staining). (C–F) Double immunostaining for dragon green fluorescein (Fluo,) 
and RIP shows examples of injected Olig2-NSCs that differentiated into OPCs. (G) The bar graph shows the number of intraventricularly 
injected Olig2-NSCs and NSCs that were found in the spinal cord of EAE Biozzi mice (n = 3, mean ± SD; *p ≤ 0.05). (H). Quantification 
of the differentiation pattern of the injected NSCs and Olig2-NSCs in the secondary lesions in the spinal cord shows that a majority of the 
Olig2-NSCs differentiated into OPCs, whereas most of the NSCs stayed undifferentiated (nestin-positive) (n = 3, mean ± SD; *p ≤ 0.05). 
Scale bars: 100 μm (for A, B) and 50 μm (for C–F).
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to survive, to differentiate into mature oligodendrocytes, 
and to remyelinate axons in the cuprizone mouse model 
for demyelination (9,31). Migratory activity of Olig2-
NSCs was evident in these studies, but limited since they 
were stereotactically injected near the site of demyelina-
tion. In the present studies, we aimed to investigate the 
migration of NSCs and Olig2-NSCs after intraventricular 
injection toward lesions in the EAE mouse model for MS. 
It is well documented that NSCs express a wide variety of 
chemokine receptors (18,33,34) and the observed migra-
tion of NSCs toward lesions and, for instance, glioblas-
toma appear to depend on CXCR3/CXCL9 and CXCR4/
CCL12 signaling (8,10,36). In order to check whether 
forced Olig2 expression did not alter the NSC-specific 
expression of chemokine receptors and change the migra-
tory capacity, we verified the expression of the major 
chemokine receptors CXCR3 and CXCR4 in Olig2-NSCs 
and their response to the ligands CXCL9 and CXCL12. 
As illustrated by in vivo bioluminescence and biofluores-
cence imaging, NSCs as well as Olig2-NSCs migrated 
to the active EAE lesions in the spinal cord, apparently 
attracted by chemokines produced only by active lesions. 
In some injection experiments with the ABH mice, we 
labeled Olig2-NSCs with large dragon green fluorophore 
particles. The presence of these intracellular particles did 
not influence the migratory capacity of these cells to EAE 
lesions as was also previously demonstrated for NSCs 
containing similar-sized magnetic particles (6).
Intraventricular injection not only at the onset of the 
first acute phase but also at the onset of the first relapse 
phase resulted in a direct migration of both NSCs and 
Olig2-NSCs toward the lesioned sites in the spinal cord. 
Obviously, the mode of application is important for the 
migratory behavior of injected cells (32); intravenous 
injection of NSCs results within 2 min in their massive 
accumulation in the lung (28), whereas direct injection 
of cells in the spinal cord near a lesioned area only result 
in their limited migration into normal areas causing addi-
tional axonal damage (16). The presence of NSCs and 
Olig2-NSCs in the lesioned spinal cord directly induced 
a significant inhibition in the further development in 
the clinical score, confirming the findings of other EAE 
implantation studies (11–13,23–27). The mechanisms of 
this protective action have been ascribed to the produc-
tion of a wide variety of trophic and immunomodulatory 
factors by NSCs that appear to reduce cell infiltration, 
Figure 11. Electron microscopy of Biozzi spinal cord after cell injections at onset of relapsing EAE. (A) Toluidine-blue 1 μm section of a 
lesion site shows the presence of many implanted cells recognizable by the labeling with black fluorophore particles. (B) Outside the lesion 
site no grafted cells can be detected. (C) Among myelinated and unmyelinated fibers (part of) a grafted Olig2-NSC (area magnified in D; 
cell outlined) containing a large labeling particle (arrow) is located. (E) Example of an (particle labeled, arrow) implanted Olig2-NSC (cell 
contour in dotted lines) contributing to remyelination of an axon. Scale bars: 10 μm (in A and B), 2 μm (in C), and 1 μm (in D and E).
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restrain dendritic cell function, and cause the selective 
death of reactive T cells (11,26,27). Most of the immu-
nomodulatory interaction between the grafted NSCs and 
immune cells in our studies must have taken place at the 
spinal cord level since we were unable to trace intraven-
tricularly injected NSCs back in peripheral organs, like 
spleen or lung; only sporadically a few injected NSCs 
could be detected in cervical lymph nodes a week after 
injection. We speculated that in particular the OPC-
primed Olig2-NSCs would additionally contribute to the 
reduction of signs with supportive remyelination activ-
ity. Remyelination activity in the spinal cord lesions by 
the injected Olig2-NSCs was not detected in the acute 
lesions but only in the relapsing disease episodes in the 
Biozzi mice. Since the immediate effect of the intraven-
tricularly injected NSCs and Olig2-NSCs on cell infiltra-
tion and inflammation apparently prevented wide-scale 
demyelination to occur in the relapse phases of EAE, the 
amount of required remyelination (and the contribution 
of Olig2-NSCs to that) was low accordingly. To really 
establish a more prominent contribution of Olig2-NSCs 
to myelin repair in EAE lesions, we would need to inject 
these cells at a later stage in the relapsing disease course, 
when demyelination indeed is a prominent component. 
However, such an experimental set-up (Olig2-NSCs injec -
tion in high score diseased animals) would currently face 
insurmountable objections by the local ethical commit-
tee for experimental animal research. Despite a similar 
anti-inflammatory action, we observed considerable dif-
ferences in the survival and differentiation in the spinal 
cord lesions between the NSCs and the Olig2-NSCs: the 
survival rate of Olig2-NSCs was significantly higher, 
presumably due to the fact that most of them differenti-
ated into OPCs, in comparison to control NSCs, where 
the majority maintained an undifferentiated state. In addi-
tion, it has been reported in some studies that Olig2 can 
support cell survival (11,35).
The most interesting finding of the present research is 
the fact that early injection of NSCs at the onset of the 
very first EAE signs of disease appears to delay and reduce 
the extent of a relapse and in case of Olig2-NSCs even 
completely prevent a relapse from occurring. Apparently, 
the presence of surviving injected NSCs and in particular 
NSC-derived OPCs in the spinal cord modify local condi-
tions and/or instruct local cells (like microglia) resulting in 
a reduced invasion and/or activity of aggressive T cells. A 
role for the peripheral lymph node system seems unlikely 
since only very sporadically injected cells were detected 
in them. An instructive mechanism by secreted factors, 
similar to suggested for implanted bone marrow cells 
and mesenchymal stem cells (e.g., 5,14,19), seems more 
likely. It has been demonstrated that, in addition to the neu-
rotrophic and anti-inflammatory factors already described 
for the NSCs (e.g., 11,15,26,27), stem cell-derived OPCs 
do produce significant amounts of chemokines and cytok-
ines among which transforming growth factor β (TGF-β), 
interleukin (IL)-6 and IL-8 (37). These factors have been 
shown to reduce blood–brain barrier permeability and 
to reduce microglia and astrocyte activation; in particu-
lar, TGF-β has been shown to mitigate EAE through the 
induction of anergy and infectious tolerance in regulatory 
T lymphocytes (30). The mechanisms behind the effects 
of implanted NSCs and Olig2-NSCs are now the subject 
of extensive detailed research since they may be of con-
siderable significance for a potential cell transplantation 
therapy for relapsing–remitting MS (RRMS) patients that 
aimed to suppress relapses and to prevent a transition 
toward the secondary progressive state.
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